185 related articles for article (PubMed ID: 19393857)
1. New chemical entities and their market penetration in Finland during the years 1996 through 2005.
Martikainen JE; Enlund H
Clin Ther; 2009 Mar; 31(3):668-76. PubMed ID: 19393857
[TBL] [Abstract][Full Text] [Related]
2. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
[TBL] [Abstract][Full Text] [Related]
3. The costs and benefits of regulations for reimbursement of new drugs.
Lundkvist J; Jönsson B; Rehnberg C
Health Policy; 2006 Dec; 79(2-3):337-44. PubMed ID: 16549221
[TBL] [Abstract][Full Text] [Related]
4. Use and reported adverse effects of new chemical entities.
Kennedy DL; Goetsch RA; Dreis MW
Am J Hosp Pharm; 1989 Mar; 46(3):558-65. PubMed ID: 2719041
[TBL] [Abstract][Full Text] [Related]
5. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
Ha D; Choi Y; Kim DU; Chung KH; Lee EK
Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
[TBL] [Abstract][Full Text] [Related]
6. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
Obradovic M; Mrhar A; Kos M
Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
[TBL] [Abstract][Full Text] [Related]
7. [Economic prescription of drugs].
Sonne J; Faber O
Ugeskr Laeger; 2004 Apr; 166(18):1695. PubMed ID: 15174414
[No Abstract] [Full Text] [Related]
8. An assessment of direct-to-consumer advertising of prescription drugs.
Calfee JE
Clin Pharmacol Ther; 2007 Oct; 82(4):357-60. PubMed ID: 17851572
[TBL] [Abstract][Full Text] [Related]
9. The quantity and quality of worldwide new drug introductions, 1982-2003.
Grabowski HG; Wang YR
Health Aff (Millwood); 2006; 25(2):452-60. PubMed ID: 16522586
[TBL] [Abstract][Full Text] [Related]
10. Do higher drug costs lead to better health?
Mintzes B; Lexchin J
Can J Clin Pharmacol; 2005; 12(1):e22-7. PubMed ID: 16055941
[TBL] [Abstract][Full Text] [Related]
11. [Reduce prescription of expensive drugs without increased value].
Furberg C
Lakartidningen; 2003 Dec; 100(49):4113. PubMed ID: 14717079
[No Abstract] [Full Text] [Related]
12. Analysis of French generic medicines retail market: why the use of generic medicines is limited.
Dylst P; Vulto A; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):795-803. PubMed ID: 25095903
[TBL] [Abstract][Full Text] [Related]
13. Doctors don't fall for the hard sell.
Randerson J
New Sci; 2003 Jun; 178(2401):10. PubMed ID: 14686412
[No Abstract] [Full Text] [Related]
14. Synthetic approaches to the 2009 new drugs.
Liu KK; Sakya SM; O'Donnell CJ; Flick AC; Li J
Bioorg Med Chem; 2011 Feb; 19(3):1136-54. PubMed ID: 21256756
[TBL] [Abstract][Full Text] [Related]
15. The burden of rheumatoid arthritis and access to treatment: determinants of access.
Lundqvist J; Kastäng F; Kobelt G; Jönsson B
Eur J Health Econ; 2008 Jan; 8 Suppl 2():S87-93. PubMed ID: 18157560
[TBL] [Abstract][Full Text] [Related]
16. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
18. [Quality reports reduce drug costs in primary health care. Stockholm County Council a model for decentralized expenditure responsibility].
Almkvist H; Bergman U; Edlert M; Juhasz-Haverinen M; Pehrsson A; Bergen-Dahl GT; Veg A; Wettermark B
Lakartidningen; 2008 Oct 15-21; 105(42):2930-4. PubMed ID: 19025150
[No Abstract] [Full Text] [Related]
19. [New drugs must henceforth be better than the current standard. What remains for physician therapy autonomy?].
Schmidt K
MMW Fortschr Med; 2006 Dec; 148(49-50):61, 63. PubMed ID: 17619334
[No Abstract] [Full Text] [Related]
20. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
Brand R
State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
[No Abstract] [Full Text] [Related]
[Next] [New Search]
